Kingworld Medicines Group Limited

SEHK:1110 Stock Report

Market Cap: HK$317.5m

Kingworld Medicines Group Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Li Sheng Zhao

Chief executive officer

CN¥1.4m

Total compensation

CEO salary percentage97.9%
CEO tenure15.6yrs
CEO ownership51.4%
Management average tenureno data
Board average tenure14yrs

Recent management updates

Recent updates

A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)

Mar 22
A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)

The Return Trends At Kingworld Medicines Group (HKG:1110) Look Promising

Nov 30
The Return Trends At Kingworld Medicines Group (HKG:1110) Look Promising

Slowing Rates Of Return At Kingworld Medicines Group (HKG:1110) Leave Little Room For Excitement

Aug 17
Slowing Rates Of Return At Kingworld Medicines Group (HKG:1110) Leave Little Room For Excitement

Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0247

May 30
Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0247

The Returns At Kingworld Medicines Group (HKG:1110) Aren't Growing

May 11
The Returns At Kingworld Medicines Group (HKG:1110) Aren't Growing

Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0247

Apr 03
Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0247

Returns On Capital At Kingworld Medicines Group (HKG:1110) Paint A Concerning Picture

Feb 07
Returns On Capital At Kingworld Medicines Group (HKG:1110) Paint A Concerning Picture

A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)

Oct 07
A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)

Kingworld Medicines Group's (HKG:1110) Returns On Capital Not Reflecting Well On The Business

Jul 05
Kingworld Medicines Group's (HKG:1110) Returns On Capital Not Reflecting Well On The Business

Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To HK$0.024

Apr 27
Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To HK$0.024

We Like These Underlying Return On Capital Trends At Kingworld Medicines Group (HKG:1110)

Aug 17
We Like These Underlying Return On Capital Trends At Kingworld Medicines Group (HKG:1110)

Kingworld Medicines Group (HKG:1110) Seems To Use Debt Rather Sparingly

Apr 24
Kingworld Medicines Group (HKG:1110) Seems To Use Debt Rather Sparingly

Returns On Capital Are Showing Encouraging Signs At Kingworld Medicines Group (HKG:1110)

Mar 29
Returns On Capital Are Showing Encouraging Signs At Kingworld Medicines Group (HKG:1110)

Kingworld Medicines Group's (HKG:1110) Shareholders Are Down 46% On Their Shares

Mar 08
Kingworld Medicines Group's (HKG:1110) Shareholders Are Down 46% On Their Shares

Are Insiders Buying Kingworld Medicines Group Limited (HKG:1110) Stock?

Feb 15
Are Insiders Buying Kingworld Medicines Group Limited (HKG:1110) Stock?

Should You Or Shouldn't You: A Dividend Analysis on Kingworld Medicines Group Limited (HKG:1110)

Jan 25
Should You Or Shouldn't You: A Dividend Analysis on Kingworld Medicines Group Limited (HKG:1110)

Will the Promising Trends At Kingworld Medicines Group (HKG:1110) Continue?

Dec 18
Will the Promising Trends At Kingworld Medicines Group (HKG:1110) Continue?

We Think Kingworld Medicines Group (HKG:1110) Can Stay On Top Of Its Debt

Dec 05
We Think Kingworld Medicines Group (HKG:1110) Can Stay On Top Of Its Debt

What We Learned About Kingworld Medicines Group's (HKG:1110) CEO Compensation

Nov 22
What We Learned About Kingworld Medicines Group's (HKG:1110) CEO Compensation

CEO Compensation Analysis

How has Li Sheng Zhao's remuneration changed compared to Kingworld Medicines Group's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

CN¥38m

Sep 30 2023n/an/a

CN¥37m

Jun 30 2023n/an/a

CN¥36m

Mar 31 2023n/an/a

CN¥29m

Dec 31 2022CN¥1mCN¥1m

CN¥23m

Sep 30 2022n/an/a

CN¥29m

Jun 30 2022n/an/a

CN¥35m

Mar 31 2022n/an/a

CN¥33m

Dec 31 2021CN¥1mCN¥1m

CN¥30m

Sep 30 2021n/an/a

CN¥26m

Jun 30 2021n/an/a

CN¥21m

Mar 31 2021n/an/a

CN¥17m

Dec 31 2020CN¥1mCN¥1m

CN¥12m

Sep 30 2020n/an/a

CN¥16m

Jun 30 2020n/an/a

CN¥20m

Mar 31 2020n/an/a

CN¥32m

Dec 31 2019CN¥2mCN¥2m

CN¥43m

Sep 30 2019n/an/a

CN¥45m

Jun 30 2019n/an/a

CN¥46m

Mar 31 2019n/an/a

CN¥44m

Dec 31 2018CN¥1mCN¥1m

CN¥41m

Sep 30 2018n/an/a

CN¥49m

Jun 30 2018n/an/a

CN¥56m

Mar 31 2018n/an/a

CN¥54m

Dec 31 2017CN¥2mCN¥1m

CN¥51m

Compensation vs Market: Li Sheng's total compensation ($USD192.61K) is about average for companies of similar size in the Hong Kong market ($USD233.25K).

Compensation vs Earnings: Li Sheng's compensation has been consistent with company performance over the past year.


CEO

Li Sheng Zhao (65 yo)

15.6yrs

Tenure

CN¥1,394,000

Compensation

Mr. Zhao Li Sheng is a Co-founder of Kingworld Medicines Group Limited and serves as its Chief Executive Officer. Mr. Zhao is responsible for Kingworld Medicines Group's overall strategic planning and busi...


Board Members

NamePositionTenureCompensationOwnership
Li Sheng Zhao
Co-Founder15.6yrsCN¥1.39m51.42%
CN¥ 163.2m
Lok San Chan
Co-Founder & Executive Director15.6yrsCN¥1.25m14.47%
CN¥ 45.9m
Xuhua Zhou
Executive Director14.7yrsCN¥503.00k0.39%
CN¥ 1.2m
Cheuk Lam Wong
Independent Non-Executive Director13.4yrsCN¥276.00kno data
Jidong Duan
Independent Non-Executive Director13.4yrsCN¥276.00kno data
Jianbin Zhang
Independent Non-Executive Director10.7yrsCN¥276.00k0.0058%
CN¥ 18.4k

14.0yrs

Average Tenure

59yo

Average Age

Experienced Board: 1110's board of directors are seasoned and experienced ( 14 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.